It is with great pleasure that LSP – the specialist European healthcare investment firm – announces the successful sale of its portfolio company Kreatech Diagnostics (NL) to Leica Biosystems (UK). A Pdf version of Leica’s press release can be found here.

Kreatech is a molecular diagnostics company focusing on the development and commercialization of innovative detection products. Kreatech’s product portfolio enables customers to detect genetic aberrations that may lead to cancer or other diseases. René Kuijten, general partner at LSP, has supported the company as lead and largest investor since the company’s early years and was a Supervisory Board member.

The sale of Kreatech further enriches LSP’s track record, which was already validated by several recent trade sales such as Okairos to GSK, Movetis to Shire, U3 Pharma to Daiichi Sankyo, Pasteuria to Syngenta, Flowcardia to Bard, BMEYE to Edwards, Kudos to AstraZeneca, Jerini to Shire and DNage to Pharming, as well as the IPO of Prosensa and Zealand Pharma. In the majority of these cases, LSP was lead and founding investor. These exits have allowed the growth of LSP as a firm.

Since inception, LSP has launched a number funds, follow-on funds and new products, raising in excess of USD 1 billion of investment capital to date. Most recently, LSP launched its Health Economics Fund, which targets investments in cost-efficient medical technology companies. Other successful investment strategies include LSP’s public healthcare investment activity that has generated triple figure returns over a five year period. As a consequence, LSP has grown to become one of the most successful global healthcare investment groups. « back to overview